Skip to main content
OpenTrials
Completed

NCT Number: NCT05341544

Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes

A prospective sham-controlled randomized clinical trial to assess the effect of low-level tragus stimulation (LLTS) in patients with frequent premature ventricular complexes (PVCs)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwell Health, New York, United States

Loading trial locations.

About this study

This is a two-center, prospective, cross-over, sham-controlled, double-blinded, randomized clinical trial. All the patients will receive a cardiac event monitor at baseline for 28 days, the patient will switch the ePatch after 14 days . Patients will be allocated to either LLTS first and then sham-stimulation, or sham-stimulation first and then LLTS. Each treatment period (sham-stimulation and LLTS) will last 10 days. The Parasym device will be used, and the patients will receive LLTS or sham-stimulation for 1 hour daily. The wash-out period between the two treatments will last 8 days. Patients will be continually monitored via event monitor for 28 days in duration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (>18 years old) but < 80 years of age
  • Symptomatic PVCs or asymptomatic PVCs with a burden > 5%
  • Intolerant to or unwilling to take beta blockers and nondihydropyridine calcium channel blockers or beta blockers and nondihydropyridine calcium channel blockers have proved ineffective

Exclusion criteria

  • Ischemic cardiomyopathy with LVEF < 40%
  • Severe heart failure (New York Heart Association Class III, or IV) or valve disease
  • Sustained ventricular tachycardia
  • Structural heart disease or myocardial scar
  • Pregnancy or nursing
  • Patients with known thyroid issues, on renal dialysis.
  • Patients with prolonged first-degree block, high degree AV block (2nd or 3rd degree), bivascular block and documented sick sinus syndrome
  • Hypotension due to autonomic dysfunction
  • Patients with cardiac implantable electronic device (ICD or PPM) , hearing aid implants or any implanted metallic or electronic device
  • Patients who have had prior cervical vagotomy
  • Patients with skin on the tragus that is broken or cracked
  • Patients with a history of baseline cardiac disease or atherosclerotic cardiovascular disease, including congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction (within 5 years) and patients diagnosed with narrowing of the arteries (carotid atherosclerosis)

Treatment and study plan

Parasym device

Device

The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.

Sham device

Device

Sham device

Primary outcomes

  1. PVC Burden

    Time frame: 28 days

    Daily PVC Count by event monitor

Secondary outcomes

  1. Quality of life survey

    Time frame: 28 days

    SF 36 QOL Score

  2. Heart Rate Variability

    Time frame: 28 days

    Daily HRV

  3. PVC Morphology

    Time frame: 28 days

    Fluctuation in PVC Morphology by event monitor

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

  • University of Oklahoma

Registry information

Official study title

Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes (NoVa-PVC)

Acronym: (NoVa-PVC)

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 22, 2022
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.